GlassScriptPhysician profile
Ayman A Hosny
NPI 1265414155
$2,211.89
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $909 · 2020: $583 · 2021: $306 · 2022: $41.06 · 2023: $204 · 2024: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $372.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $463.42 | 2019-2020 | |
| Amgen INC. | $303.57 | 2019-2023 | Repatha |
| Abbott Laboratories | $180.88 | 2019-2024 | Gallant |
| E.R. Squibb & Sons, L.L.C. | $156.08 | 2019-2021 | |
| Heartflow, INC. | $120.89 | 2020 | |
| Pfizer INC. | $112.49 | 2019-2021 | |
| Amarin Pharma, INC. | $102.71 | 2019-2021 | |
| Boston Scientific Corporation | $87.58 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $75.20 | 2019 | |
| Bardy Diagnostics, INC. | $68.58 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $59.97 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $57.41 | 2019 | |
| Smith+Nephew, INC. | $56.07 | 2024 | Collagenase Santyl |
| Janssen Pharmaceuticals, INC | $55.04 | 2023-2024 | Xarelto |
| Biotronik INC. | $46.11 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $39.10 | 2023 | |
| Novo Nordisk INC | $37.48 | 2019-2023 | Ozempic, Rybelsus |
| Medtronic, INC. | $35.47 | 2021-2024 | Attain Command + Surevalve |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.92 | 2019-2023 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $30.38 | 2024 | |
| Daiichi Sankyo INC. | $27.37 | 2023 | Injectafer |
| Abiomed | $20.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.84 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.54 | 2021 | |
| Edwards Lifesciences Corporation | $13.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Hosny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.